SymBio Pharmaceuticals LimitedJP:4582
| Dec 31,
2022 | Dec 31,
2023 |
|---|
| Profit (loss) before income taxes | 2,106 | -1,195 |
|---|
| Depreciation | 98 | 96 |
|---|
| Amortization of guarantee deposits | 1 | 2 |
|---|
| Impairment losses | - | 561 |
|---|
| Share-based payment expenses | 105 | 82 |
|---|
| Increase (decrease) in retirement benefit liability | 1 | 0 |
|---|
| Increase (decrease) in provision for merchandise and finished goods switching | -171 | -16 |
|---|
| Increase (decrease) in provision for office transfer expenses | - | 17 |
|---|
| Interest income | -0 | -12 |
|---|
| Foreign exchange losses (gains) | -370 | -132 |
|---|
| Commission expenses | 57 | 13 |
|---|
| Share issuance costs | 46 | 11 |
|---|
| Gain on reversal of share acquisition rights | -106 | -101 |
|---|
| Loss on retirement of non-current assets | 1 | 8 |
|---|
| Decrease (increase) in trade receivables | 63 | 1,172 |
|---|
| Decrease (increase) in inventories | -83 | 237 |
|---|
| Decrease (increase) in prepaid expenses | -65 | 91 |
|---|
| Increase/decrease in consumption taxes payable/consumption taxes refund receivable | -271 | -213 |
|---|
| Decrease (increase) in other current assets | -90 | -23 |
|---|
| Increase (decrease) in trade payables | -23 | -47 |
|---|
| Increase (decrease) in accounts payable - other | 685 | -310 |
|---|
| Increase (decrease) in other current liabilities | -106 | -66 |
|---|
| Other, net | 158 | -2 |
|---|
| Subtotal | 2,034 | 172 |
|---|
| Interest and dividends received | 0 | 0 |
|---|
| Commitment fee paid | -57 | -12 |
|---|
| Income taxes paid | -364 | -355 |
|---|
| Net cash provided by (used in) operating activities | 1,614 | -195 |
|---|
| Purchase of property, plant and equipment | -2 | -204 |
|---|
| Purchase of intangible assets | -46 | -29 |
|---|
| Payments of leasehold and guarantee deposits | - | -144 |
|---|
| Proceeds from refund of leasehold and guarantee deposits | 0 | - |
|---|
| Net cash provided by (used in) investing activities | -47 | -377 |
|---|
| Proceeds from issuance of shares resulting from exercise of share acquisition rights | 0 | 0 |
|---|
| Proceeds from issuance of share acquisition rights | 14 | - |
|---|
| Payments for issuance of shares | -46 | -12 |
|---|
| Proceeds from issuance of shares | 662 | 692 |
|---|
| Purchase of treasury shares | -2 | -1 |
|---|
| Proceeds from disposal of treasury shares | 0 | 0 |
|---|
| Net cash provided by (used in) financing activities | 628 | 680 |
|---|
| Effect of exchange rate change on cash and cash equivalents | 214 | 126 |
|---|
| Net increase (decrease) in cash and cash equivalents | 2,409 | 234 |
|---|
| Increase in cash and cash equivalents resulting from inclusion of subsidiaries in consolidation | 14 | - |
|---|